This is a preview. Check to see if you have access to the full video. Check access
A metastatic brain tumor originates from a primary tumor derived from tissue outside the central nervous system (CNS) or the surrounding meninges. The tumor secondarily disperses to involve the cranium, meninges, or brain parenchyma.
Treatment of metastatic brain lesions has a history of contention with regard to its surgical indications. However, with recent improvements in imaging, the indications for resection of metastatic tumors have broadened.
Moreover, two pivotal prospective randomized studies, published in 1990 and 1993, supported resection of metastatic brain tumors along with the standard regimen of radiation therapy. In these studies, resection provided a survival advantage over radiation therapy alone.
Diagnosis and Evaluation
A comprehensive oncologic evaluation of a patient with a known metastatic brain lesion is imperative to the feasibility of intracranial resection. The first step in the evaluation process includes staging or assessment of the extent of systemic and intracranial involvement. This evaluation is often performed via diagnostic imaging and with the input of our neuro-oncology colleagues. The most common imaging modalities for assessment of systemic disease include computed tomography (CT) of the chest, abdomen, and pelvis with and without contrast and selective use of positron emission tomography (PET) for certain tumor subtypes.
Magnetic resonance imaging (MRI) determines the extent of CNS involvement. This modality provides superior parenchymal resolution, allowing better accuracy in defining the number of tumors, their margins and the degree of peritumoral edema and mass effect.
Contrast-enhanced MRI sequences will detect small asymptomatic lesions (<5 mm); lesions of this size are frequently overlooked on CT scans. The anatomic data acquired from the MRI is crucial for planning the approach for resection. Although inferior to the MRI in providing parenchymal detail, CT scans are particularly helpful in the evaluation of bony erosion, particularly when the lesions involve the skull base and calvarium.
If an intracranial lesion is identified prior to the diagnosis of a systemic malignancy, a variety of possible etiologies are included in the list of differential diagnosis. These entities include intra-axial primary tumors (gliomas), extra-axial primary tumors (meningioma, schwannoma), vascular anomalies (thrombosed aneurysm, vascular malformation, hematoma), intracranial abscess, demyelinating process, and granulomatous disease.
The patient’s history will shorten the list of differential diagnosis. If a patient has a history of a primary malignancy outside the CNS, a metastatic tumor is obviously the most likely etiology. Known history of a primary malignancy with infrequent CNS involvement (e.g., prostate cancer), a remote history of systemic malignancy and predisposition to infection are important historical considerations.
Indications for Surgery
The appropriateness of surgical resection for intracranial metastatic disease requires individualized considerations. The following factors play an important role in the decision-making process: 1) the extent of systemic metastatic spread and intra-axial involvement, 2) type of malignancy, 3) primary tumor’s response to chemotherapy and/or radiation, 4) size, location, and multiplicity of the intra-axial lesions, and most importantly 5) the overall life expectancy of the patient.
Other classifications of central nervous system involvement can also be useful in defining the indications for resection. These classifications include:
- A single metastatic lesion of the parenchyma or meninges,
- two or three metastatic lesions of the parenchyma or meninges, but not both occurring simultaneously, or
- three or more metastatic lesions of the parenchyma or meninges, including patients with simultaneous parenchymal and leptomeningeal disease.
A single intracranial metastatic lesion associated with a primary malignancy that demonstrates controlled systemic involvement and is less than sufficiently radiosensitive should be resected. This category also includes intracranial lesions occurring with an unknown primary malignancy.
The surgical management of two or three parenchymal metastatic lesions is controversial. I often do not offer surgical resection to these patients, especially if the patient is functionally impaired or suffers from advanced systemic disease. Instead, I recommend adjuvant therapies. However, special consideration may be given to patients with limited systemic disease who suffer from two nearby lesions, both accessible via a single craniotomy.
Three or more parenchymal lesions or simultaneous parenchymal and leptomeningeal involvement are contraindications to surgical intervention because limited resection will most likely not affect the natural history of advanced metastatic disease.
The lack of data supporting a survival benefit among patients in the latter two groups is recognized in the surgical community. Limited data regarding resection of all metastatic lesions combined with radiation therapy from a cohort of patients with multifocal intracranial metastatic disease demonstrated superiority to treatment by standard radiation therapy alone. Despite these results, more data are necessary before considering operative intervention in these more controversial groups.
Patients suffering from metastatic disease are more likely to be medially compromised, and therefore a full preoperative medical assessment is warranted. The patient may have undergone prior pneumonectomy for lung cancer. Pulmonary function testing is necessary to minimize the risk of respiratory compromise postoperatively. Upon stratifying the patient’s risk factors, it is advisable to optimize the neurologic status and medical status of each patient before the operation.
RESECTION OF METASTATIC LESIONS
The location of an intracranial tumor determines the nuances of technique for its resection. Two adjacent metastatic lesions may be resected concurrently. For general tenets of craniotomy and exposure, please refer to the Cranial Approaches volume.
Following is a discussion of techniques for removal of a cerebellar metastatic lesion. Similar principles apply to all such lesions.
Special considerations may apply to patients who have undergone a pneumonectomy. The lateral position may place the remaining lung in the dependent direction, thereby increasing the risk for respiratory compromise. In these patients, the lateral position should be avoided or the remaining lung should not be placed in the dependent position.
Cortical stimulation or phase reversal mapping techniques may be used for accessing supratentorial lesions in the vicinity of the functional cortices. These techniques guide the operative pathways that are least likely to disrupt function. Please refer to the Sensorimotor Mapping for Glioma chapter for more details.
The suggested operative trajectories for different intra-axial metastatic lesions may be classified into eight different categories; five are for supratentorial and three are infratentorial pathologies. These classifications are reviewed in Table 1 below.
Tumors located along the superficial convexity of the hemispheres, either cortical or subcortical, and within 2.5 cm of the surface, are amendable to a transcortical or trans-sulcal approach. Compared with the transcortical approach, the transsulcal pathway may sacrifice sulcal vasculature, which can be avoided via the transcortical approach. The trans-sulcal route may also place both bordering gyri at risk of injury. For these reasons, I usually prefer the transcortical route.
Generally, tumors in the superficial 1 cm of the cortical surface are best approached through the transcortical route as opposed to subcortical tumors greater than 1 cm deep to the cerebral convexity, which are best approached via the trans-sulcal trajectory. Larger lesions can be approached through a combination of transcortical and trans-sulcal routes.
The interhemispheric approach is generally reserved for medial parenchymal tumors within the cortical and subcortical regions. For additional details on approach to ventricular tumors, see the Diagnosis and Technical Principles in Intraventricular Surgery chapter.
Infratentorial lesions present a challenge because of the limitations in the anatomic approach. In most cases, the posterior transparenchymal route is appropriate for reaching dorsal lesions. For vermian metastatic tumors, a vermian split may be performed, although this maneuver carries a risk of vermian split syndrome (a small risk since the tumor has created most of the operative corridor).
Upon exposure of the mass, there are several important surgical features unique to metastatic lesions. The mass is firm and devoid of neuronal tissue and has well-demarcated margins. These lesions appear grossly less infiltrative than gliomas.
There is an easily recognizable pseudocapsule surrounding the metastatic mass, which can serve as an anatomic landmark. The pseudocapsule is a result of the gliosis in response to the malignant tumor.
I attempt an en bloc resection of the entire firm mass, using the pseudocapsule or the peri-pseudocapsule parenchyma as a landmark. Dissection along the pseudocapsule circumferentially devascularizes the tumor mass. This is an important step in the end goal of an en bloc resection because the tumor mass is usually vascular.
Any unintentional entry into the tumor mass before its devascularization may generate bleeding that is difficult to control because of an unpredictable vascularization pattern. This is particularly important during resection of highly vascular metastatic tumors such as medullary thyroid cancer, renal cell carcinoma, and melanoma. The en bloc resection technique also has the potential advantage of decreasing the risk of inadvertent tumor seeding from the resection cavity.
An en bloc resection should be attempted for lesions measuring less than 3 cm in diameter. For larger lesions, brain mobilization is most likely required to facilitate en bloc resection. Any cystic component of the mass should be drained first to create space for tumor manipulation. Subtotal circumferential devascularization allows piecemeal removal of large lesions not amenable to en bloc removal.
Larger tumors are more likely than the smaller spherical lesions to possess irregular and asymmetric nodules hidden within the adjacent white matter. Therefore, the surgeon should be aware of resection cavity bleeding as a potential indicator of residual tumor during excision of larger masses.
Despite their well-defined gross appearance and demarcated borders, metastatic lesions are invasive, and metastatic cells can be found up to 10 mm away from the original tumor mass. Therefore, I attempt to resect at least a 5-mm peritumoral margin around the mass to decrease the risk of recurrence. This goal cannot always be achieved, particularly in the vicinity of functional cortices and white matter tracts.
If any of the vital vascular structures (i.e., the middle cerebral artery) are encased by the tumor, subtotal removal is warranted. A small rim of tumor is left behind. Any neurologic impairment caused by the procedure offsets the survival advantage gained by resection.
I avoid calvarial defects; chemotherapy and radiation therapy further promote bone loss and osteopenia. The thin bone combined with a calvarial defect and reduced scalp hair can increase the visibility of skull defects and lead to cosmetic deformities.
Cerebral edema is a particular concern for these patients postoperatively. Therefore liberal continuance of corticosteroids postoperatively is a recommended precaution to avoid this complication. The dose should be gradually tapered as tolerated.
Pearls and Pitfalls
- Extracapsular dissection of metastatic tumors minimizes bleeding that can interfere with microsurgical resection.
Contributor: Benjamin K. Hendricks, MD
Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg. 1993; 79: 210-216.
Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B. A randomized trial of surgery in the treatment of single metastasis to the brain. N Engl J Med. 1990; 322: 494-500.
Shepard SR, Gutin PH. Metastatic brain tumors, in Sekhar LN, Fessler RG (eds): Atlas of Neurosurgical Techniques: Brain. Thieme, 2011
Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR, et al. Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993; 33: 583-590.
Please login to post a comment.